Description |
ubiquitin specific peptidase 37 |
cyclin A2 |
Image |
|
|
GO Annotations |
Cellular Component |
|
|
Molecular Function |
|
|
Biological Process |
|
|
Pathways |
|
|
Drugs |
|
- 4-(2,4-Dimethyl-Thiazol-5-Yl)-Pyrimidin-2-Ylamine
- 6-O-Cyclohexylmethyl Guanine
- [4-(2-Amino-4-Methyl-Thiazol-5-Yl)-Pyrimidin-2-Yl]-(3-Nitro-Phenyl)-Amine
- 4-(2,4-Dimethyl-1,3-thiazol-5-yl)-N-[4-(trifluoromethyl)phenyl]-2-pyrimidinamine
- 4-[(7-OXO-7H-THIAZOLO[5,4-E]INDOL-8-YLMETHYL)-AMINO]-N-PYRIDIN-2-YL-BENZENESULFONAMIDE
- N-(3-cyclopropyl-1H-pyrazol-5-yl)-2-(2-naphthyl)acetamide
- 2-ANILINO-6-CYCLOHEXYLMETHOXYPURINE
- O6-CYCLOHEXYLMETHOXY-2-(4'-SULPHAMOYLANILINO) PURINE
- (2S)-N-[(3E)-5-Cyclopropyl-3H-pyrazol-3-ylidene]-2-[4-(2-oxo-1-imidazolidinyl)phenyl]propanamide
- N-cyclopropyl-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amine
- 6-CYCLOHEXYLMETHOXY-2-(3'-CHLOROANILINO) PURINE
- 5-[5,6-BIS(METHYLOXY)-1H-BENZIMIDAZOL-1-YL]-3-{[1-(2-CHLOROPHENYL)ETHYL]OXY}-2-THIOPHENECARBOXAMIDE
- 4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]-2-FURYL}-N-METHYLBENZENESULFONAMIDE
- 4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}BENZENESULFONAMIDE
- 4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}-2-(TRIFLUOROMETHYL)BENZENESULFONAMIDE
- 4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}BENZOIC ACID
- N-[4-(2,4-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2-YL]-N',N'-DIMETHYL-BENZENE-1,4-DIAMINE
- 4-{[5-(CYCLOHEXYLOXY)[1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL]AMINO}BENZENESULFONAMIDE
- 1-(3,5-DICHLOROPHENYL)-5-METHYL-1H-1,2,4-TRIAZOLE-3-CARBOXYLIC ACID
- 4-(4-methoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-amine
- 4-(4-propoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-amine
- HYDROXY(OXO)(3-{[(2Z)-4-[3-(1H-1,2,4-TRIAZOL-1-YLMETHYL)PHENYL]PYRIMIDIN-2(5H)-YLIDENE]AMINO}PHENYL)AMMONIUM
- 4-Methyl-5-[(2Z)-2-{[4-(4-morpholinyl)phenyl]imino}-2,5-dihydro-4-pyrimidinyl]-1,3-thiazol-2-amine
- 6-CYCLOHEXYLMETHYLOXY-2-(4'-HYDROXYANILINO)PURINE
- 4-(6-CYCLOHEXYLMETHOXY-9H-PURIN-2-YLAMINO)--BENZAMIDE
- 3-(6-CYCLOHEXYLMETHOXY-9H-PURIN-2-YLAMINO)-BENZENESULFONAMIDE
- (2R)-2-{[4-(benzylamino)-8-(1-methylethyl)pyrazolo[1,5-a][1,3,5]triazin-2-yl]amino}butan-1-ol
- 3-({2-[(4-{[6-(CYCLOHEXYLMETHOXY)-9H-PURIN-2-YL]AMINO}PHENYL)SULFONYL]ETHYL}AMINO)PROPAN-1-OL
- 1-methyl-8-(phenylamino)-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxylic acid
- (2R)-2-({9-(1-methylethyl)-6-[(4-pyridin-2-ylbenzyl)amino]-9H-purin-2-yl}amino)butan-1-ol
- 1-[4-(AMINOSULFONYL)PHENYL]-1,6-DIHYDROPYRAZOLO[3,4-E]INDAZOLE-3-CARBOXAMIDE
- 4-{[4-AMINO-6-(CYCLOHEXYLMETHOXY)-5-NITROSOPYRIMIDIN-2-YL]AMINO}BENZAMIDE
- Variolin B
|
Diseases |
|
|
GWAS |
- Body mass index ( 25673413)
- Height ( 28552196)
- High light scatter reticulocyte count ( 32888494)
- High light scatter reticulocyte percentage of red cells ( 32888494)
- Hip circumference adjusted for BMI ( 34021172)
- Male-pattern baldness ( 28196072)
- Post bronchodilator FEV1/FVC ratio ( 26634245)
- Reticulocyte count ( 32888494)
- Reticulocyte fraction of red cells ( 32888494)
- Waist circumference adjusted for body mass index ( 34021172)
|
|
Interacting Genes |
6 interacting genes:
CCNA2
MYC
RHOU
SNAI1
UBC
YWHAG
|
49 interacting genes:
ARID4A
BRCA1
BRCA2
BTG1
BUB1B
CALM1
CDC20
CDC25C
CDC6
CDK1
CDK2
CDK3
CDKN1A
CDKN1B
CDT1
DRD2
DTNBP1
E2F1
E2F3
FANCC
FEN1
H1-1
H1-5
HERC5
HIRA
ITGB3BP
KAT2B
MAD2L1
MAGEA11
MYBL2
NFYA
PGR
POLA1
PRC1
PSMD4
PTMA
RAD23A
RB1
RBL1
RBL2
RPA1
SKP1
SKP2
SP1
TAF1
TP53
TRAF3IP1
UBTF
USP37
|
Entrez ID |
57695 |
890 |
HPRD ID |
07506 |
00453 |
Ensembl ID |
ENSG00000135913
|
ENSG00000145386
|
Uniprot IDs |
A0A024R416
Q86T82
|
P20248
|
PDB IDs |
3U12
|
1E9H
1FIN
1FVV
1GY3
1H1P
1H1Q
1H1R
1H1S
1H24
1H25
1H26
1H27
1H28
1JST
1JSU
1OGU
1OI9
1OIU
1OIY
1OKV
1OKW
1OL1
1OL2
1P5E
1PKD
1QMZ
1URC
1VYW
2BKZ
2BPM
2C4G
2C5N
2C5O
2C5V
2C5X
2C6T
2CCH
2CCI
2CJM
2I40
2IW6
2IW8
2IW9
2UUE
2UZB
2UZD
2UZE
2UZL
2V22
2WEV
2WFY
2WHB
2WIH
2WIP
2WMA
2WMB
2WPA
2WXV
2X1N
3EID
3EJ1
3EOC
3F5X
4BCK
4BCM
4BCN
4BCP
4CFM
4CFN
4CFU
4CFV
4CFW
4CFX
4EOI
4EOJ
4EOK
4EOL
4EOM
4EON
4EOO
4EOP
4EOQ
4EOR
4EOS
4FX3
5CYI
5IF1
5LMK
5NEV
6ATH
6GVA
6P3W
6Q6G
6Q6H
6RIJ
6SG4
7B5L
7B5R
|
Enriched GO Terms of Interacting Partners? |
|
|
Tagcloud ? |
|
|
Tagcloud (Difference) ? |
|
|
Tagcloud (Intersection) ? |
|